Log in

NASDAQ:QTNTQuotient Stock Price, Forecast & News

-0.29 (-4.10 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $6.79
50-Day Range
MA: $7.80
52-Week Range
Now: $6.79
Volume469,993 shs
Average Volume662,842 shs
Market Capitalization$547.34 million
P/E RatioN/A
Dividend YieldN/A
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Read More
Quotient logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.81 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:QTNT



Sales & Book Value

Annual Sales$32.66 million
Book Value($0.07) per share


Net Income$-102,770,000.00
Net Margins-313.16%


Market Cap$547.34 million
Next Earnings Date11/2/2020 (Estimated)
-0.29 (-4.10 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Quotient (NASDAQ:QTNT) Frequently Asked Questions

How has Quotient's stock been impacted by COVID-19 (Coronavirus)?

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, QTNT stock has increased by 46.3% and is now trading at $6.79.
View which stocks have been most impacted by Coronavirus

When is Quotient's next earnings date?

Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Quotient

How were Quotient's earnings last quarter?

Quotient Ltd (NASDAQ:QTNT) posted its earnings results on Monday, August, 3rd. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.01.
View Quotient's earnings history

What guidance has Quotient issued on next quarter's earnings?

Quotient updated its FY 2021 Pre-Market earnings guidance on Monday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $32-34 million, compared to the consensus revenue estimate of $36 million.

Has Quotient been receiving favorable news coverage?

Media coverage about QTNT stock has trended negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Quotient earned a daily sentiment score of -2.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Quotient

Who are some of Quotient's key competitors?

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Verastem (VSTM), Gilead Sciences (GILD), Novavax (NVAX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL) and Clovis Oncology (CLVS).

Who are Quotient's key executives?

Quotient's management team includes the following people:
  • Mr. Franz Walt, CEO & Director (Age 60)
  • Mr. Jeremy Stackawitz, Pres (Age 44)
  • Mr. Edward Farrell, Pres (Age 49)
  • Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
  • Mr. John Allan, Corp. Sr. VP & CTO

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TimesSquare Capital Management LLC (3.46%), Swiss National Bank (0.17%), Roubaix Capital LLC (0.14%), M&T Bank Corp (0.12%), DAVENPORT & Co LLC (0.12%) and New York State Common Retirement Fund (0.07%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd.
View institutional ownership trends for Quotient

Which major investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, DAVENPORT & Co LLC, Swiss National Bank, and Arizona State Retirement System. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz, and Roland Boyd.
View insider buying and selling activity for Quotient

Which major investors are buying Quotient stock?

QTNT stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, New York State Common Retirement Fund, SG Americas Securities LLC, State Board of Administration of Florida Retirement System, M&T Bank Corp, Virtu Financial LLC, UBS Group AG, and Ameritas Investment Partners Inc.. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $6.79.

How big of a company is Quotient?

Quotient has a market capitalization of $547.34 million and generates $32.66 million in revenue each year. The company earns $-102,770,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

What is Quotient's official website?

The official website for Quotient is www.quotientbd.com.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.